Sequential or Concomitant Inhibition of Cyclin-Dependent Kinase 4/6 Before mTOR Pathway in Hormone-Positive HER2 Negative Breast Cancer: Biological Insights and Clinical Implications

Sequential or Concomitant Inhibition of Cyclin-Dependent Kinase 4/6 Before mTOR Pathway in Hormone-Positive HER2 Negative Breast Cancer: Biological Insights and Clinical Implications

About 75% of all breast cancers are hormone receptor-positive (HR+). However, the efficacy of endocrine therapy is limited due to the high rate of either pre-existing or acquired resistance. In this work we reconstructed the pathways around estrogen receptor (ER), mTOR, and cyclin D in order to comp...

Full description

Bibliographic Details
Main Authors: Giulia Occhipinti, Emanuela Romagnoli, Matteo Santoni, Alessia Cimadamore, Giulia Sorgentoni, Monia Cecati, Matteo Giulietti, Nicola Battelli, Alessandro Maccioni, Nadia Storti, Liang Cheng, Giovanni Principato, Rodolfo Montironi, Francesco Piva
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-04-01
Series:Frontiers in Genetics
Subjects:
breast cancer
estrogen receptor
cyclin-dependent kinases (CDKs)
CDK inhibitors
mechanisms of resistance
Online Access:https://www.frontiersin.org/article/10.3389/fgene.2020.00349/full

Internet

https://www.frontiersin.org/article/10.3389/fgene.2020.00349/full

Similar Items